{"nctId":"NCT00703118","briefTitle":"A Safety and Effectiveness Study of Telaprevir in Chronic, Genotype 1, Hepatitis C Patients That Failed Previous Standard Treatment","startDateStruct":{"date":"2008-10"},"conditions":["Hepatitis C, Chronic"],"count":663,"armGroups":[{"label":"Group A: T12/PR48","type":"EXPERIMENTAL","interventionNames":["Drug: Telaprevir","Drug: Peg-IFN-alfa-2a","Drug: Ribavirin","Drug: Placebo"]},{"label":"Group B: T12(DS)/PR48","type":"EXPERIMENTAL","interventionNames":["Drug: Telaprevir","Drug: Peg-IFN-alfa-2a","Drug: Ribavirin","Drug: Placebo"]},{"label":"Group C: Pbo/PR48","type":"EXPERIMENTAL","interventionNames":["Drug: Peg-IFN-alfa-2a","Drug: Ribavirin","Drug: Placebo"]}],"interventions":[{"name":"Telaprevir","otherNames":[]},{"name":"Peg-IFN-alfa-2a","otherNames":[]},{"name":"Ribavirin","otherNames":[]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Patient must have chronic hepatitis C infection (genotype 1) with HCV RNA level \\>= 1000 IU/mL\n* Patient must have failed at least 1 prior course of Peg-IFN/RBV therapy (standard treatment)\n* Patient must be willing to use 2 effective methods of birth control for up to 7 months after last dose of study medication\n\nExclusion Criteria:\n\n* Patient is a previous non-responder that is classified as a viral breakthrough case\n* Patient is infected with Hepatitis C virus, genotype 1, exhibiting more than one subtype\n* Patient has Hepatitis C virus, genotype 1, and exhibits co-infection with any other genotype\n* Evidence of decompensated liver disease\n* Patient has condition that requires use of systemic corticosteroids","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"70 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Participants With Sustained Virologic Response (SVR) 24 Weeks After the Last Planned Dose of Study Medication - SVR24 Planned","description":"SVR24 planned is defined as having undetectable plasma Hepatitis C virus (HCV) ribonucleic acid (RNA) levels 24 weeks after the last planned dose of study medication.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"171","spread":null},{"groupId":"OG001","value":"175","spread":null},{"groupId":"OG002","value":"22","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants Acheiving Rapid Virologic Response (RVR) at Week 4","description":"RVR was defined as having undetectable Hepatitis C virus (HCV) ribonucleic acid (RNA) at Week 4.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"152","spread":null},{"groupId":"OG001","value":"188","spread":null},{"groupId":"OG002","value":"3","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants Acheiving Undetectable Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Levels at Week 48 (End of Treatment)","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"184","spread":null},{"groupId":"OG001","value":"191","spread":null},{"groupId":"OG002","value":"49","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Sustained Virologic Response (SVR) 12 Weeks After the Last Planned Dose of Study Medication - SVR12 Planned","description":"SVR12 planned was defined as having undetectable plasma Hepatitis C virus (HCV) ribonucleic acid (RNA) levels 12 weeks after the last planned dose of study medication (SVR12 planned).","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"175","spread":null},{"groupId":"OG001","value":"178","spread":null},{"groupId":"OG002","value":"22","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants Who Meet the Telaprevir Stopping Rule at Week 4, Week 6, or Week 8","description":"Telaprevir stopping rule is defined as having Hepatitis C virus (HCV) ribonucleic acid (RNA) levels \\>100 IU/mL at Week 4, Week 6, or Week 8 after start of telaprevir.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"16","spread":null},{"groupId":"OG001","value":"14","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants Who Have Viral Relapse During Entire Follow-up Period (up to Week 72)","description":"Viral relapse was defined as having confirmed detectable Hepatitis C virus (HCV) ribonucleic acid (RNA) levels during entire follow-up period (up to Week 72).","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"26","spread":null},{"groupId":"OG001","value":"27","spread":null},{"groupId":"OG002","value":"33","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in log10 Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) at Week 4","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.5","spread":"1.06"},{"groupId":"OG001","value":"-2.0","spread":"1.42"},{"groupId":"OG002","value":"-1.9","spread":"1.40"}]}]}]},{"type":"SECONDARY","title":"Number of Participants Acheiving Extended Rapid Virologic Response at Week 4 and Week 12","description":"Extended rapid virologic response was defined as undetectable Hepatitis C virus (HCV) ribonucleic acid (RNA) levels.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"141","spread":null},{"groupId":"OG001","value":"180","spread":null},{"groupId":"OG002","value":"3","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":18,"n":266},"commonTop":["Fatigue","Pruritus","Headache","Rash","Influenza like illness"]}}}